Skip to main content
Erschienen in: Lung 3/2005

01.06.2005

Angiogenic Factors and Angiogenesis Inhibitors in Exudative Pleural Effusions

verfasst von: Eva Ruiz, MD, Carmen Alemán, MD, José Alegre, MD, Jasone Monasterio, MD, Rosa Ma Segura, PhD, Lluis Armadans, MD, Ana Vázquez, Ph, Teresa Soriano, Ph, Tomás Fernández de Sevilla, MD

Erschienen in: Lung | Ausgabe 3/2005

Einloggen, um Zugang zu erhalten

Abstract

The angiogenesis system has been implicated in inflammatory and neoplastic processes; nevertheless, it has been little studied in relation to the pleural space. Our aim is to analyze pleural and plasma levels of the activators-vascular endothelial growth factor, basic fibroblastic growth factor, and inhibitors-endostatin and thrombospondin-1 and to estimate the association between these factors and related biochemical markers. We analyzed pleural fluid from 105 patients with one of the following types of pleural effusion: empyema or complicated parapneumonic, non-complicated parapneumonic, tuberculous, neoplastic and transudative. Angiogenesis activators were higher in exudates than in transudates (p < 0.001) and in empyema than in non-complicated parapneumonic patients (p < 0.001). Endostatin showed no significant differences. Trombospondin-1 showed higher levels in exudates than in transudates and in empyema than in non-complicated parapneumonic effusions (p < 0.001). In pleural exudates there was a positive correlation of angiogenesis activators and trombospondin-1 with low glucose and pH and high LDH. There was no correlation between pleural and plasma levels of the angiogenesis factors. We conclude that exudative pleural effusions showed higher vascular endothelial growth factor, basic-fibroblastic growth factor and trombospondin-1 values than transudative effusions -that associated to low glucose and pH, and high LDH. There was no correlation between pleural and plasma concentrations, suggesting a compartmentalized response.
Literatur
1.
Zurück zum Zitat Ruckdeschel JC1995Management of malignant pleural effusionsSeminars Oncology225863 Ruckdeschel JC1995Management of malignant pleural effusionsSeminars Oncology225863
2.
Zurück zum Zitat Jurado Gámez B1997Neumonia y derrame pleural. Manejo terapeuticoAn Med Interna (Madrid)14419424 Jurado Gámez B1997Neumonia y derrame pleural. Manejo terapeuticoAn Med Interna (Madrid)14419424
3.
Zurück zum Zitat Antony, VB, Sahn, SA, Mossman, B, Gail, DB, Kalica, A 1992Pleural cell biology in health and diseaseAm Rev Respir Dis14512361239PubMed Antony, VB, Sahn, SA, Mossman, B, Gail, DB, Kalica, A 1992Pleural cell biology in health and diseaseAm Rev Respir Dis14512361239PubMed
4.
Zurück zum Zitat Kroegel, C, Antony, VB 1997Immunobiology of pleural inflammation: potential implications for pathogenesis, diagnosis and therapyEur Respir J1024112418CrossRefPubMed Kroegel, C, Antony, VB 1997Immunobiology of pleural inflammation: potential implications for pathogenesis, diagnosis and therapyEur Respir J1024112418CrossRefPubMed
5.
Zurück zum Zitat Antony, VB, Mohammed, K 1999Pathophysiology of pleural space infectionsSemin Respir Infect14917PubMed Antony, VB, Mohammed, K 1999Pathophysiology of pleural space infectionsSemin Respir Infect14917PubMed
6.
Zurück zum Zitat Mohhamed, KA, Nasreen, N, Hardwick, J, et al. 2001Bacterial induction of pleural mesothelial monolayer barrier dysfunctionAm J Phisiol Lung Cell Mol Physiol281L119L125 Mohhamed, KA, Nasreen, N, Hardwick, J,  et al. 2001Bacterial induction of pleural mesothelial monolayer barrier dysfunctionAm J Phisiol Lung Cell Mol Physiol281L119L125
7.
Zurück zum Zitat Thickett, DR, Armstrong, L, Millar, AB 1999Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusionsThorax54707710PubMed Thickett, DR, Armstrong, L, Millar, AB 1999Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusionsThorax54707710PubMed
8.
Zurück zum Zitat Grove, CS, Gary Lee, YC 2002Vascular endothelial growth factor: the key mediator in pleural effusion formationCurr Opin Pulm Med8294301CrossRefPubMed Grove, CS, Gary Lee, YC 2002Vascular endothelial growth factor: the key mediator in pleural effusion formationCurr Opin Pulm Med8294301CrossRefPubMed
10.
Zurück zum Zitat Folkman, J, Shing, Y 1992AngiogenesisJ Biol Chem2671093110934PubMed Folkman, J, Shing, Y 1992AngiogenesisJ Biol Chem2671093110934PubMed
11.
12.
Zurück zum Zitat Hanahan, D, Folkman, J 1996Patterns and emerging mechanisms of the angiogenic switch during tumorigenesisCell86353364CrossRefPubMed Hanahan, D, Folkman, J 1996Patterns and emerging mechanisms of the angiogenic switch during tumorigenesisCell86353364CrossRefPubMed
14.
Zurück zum Zitat Bussolino, F, Mantovani, A, Persico, G 1997Molecular mechanisms of blood vessel formationTIBS22251256PubMed Bussolino, F, Mantovani, A, Persico, G 1997Molecular mechanisms of blood vessel formationTIBS22251256PubMed
15.
Zurück zum Zitat Iruela-Arispe, ML, Dvorak, HF 1997Angiogenesis: a dynamic balance of stimulators and inhibitorsThromb and Haemost78672677 Iruela-Arispe, ML, Dvorak, HF 1997Angiogenesis: a dynamic balance of stimulators and inhibitorsThromb and Haemost78672677
16.
Zurück zum Zitat Ishimoto, O, Saijo, Y, Narumi, K 2002High level of vascular endothelial growth factor in hemorrhagic pleural effusion of cancerOncology637075CrossRefPubMed Ishimoto, O, Saijo, Y, Narumi, K 2002High level of vascular endothelial growth factor in hemorrhagic pleural effusion of cancerOncology637075CrossRefPubMed
17.
18.
Zurück zum Zitat O’Reilly, MS, Boehm, T, Shing, Y, et al. 1997Endostatin: an endogenous inhibitor of angiogenesis and tumor growthCell88277285CrossRefPubMed O’Reilly, MS, Boehm, T, Shing, Y,  et al. 1997Endostatin: an endogenous inhibitor of angiogenesis and tumor growthCell88277285CrossRefPubMed
19.
Zurück zum Zitat Sumi, M, Kagohashi, K, Satoh, H, Ishikawa, H, Funayama, Y, Sekizawa, K 2003Endostatin levels in exudative pleural effurfsionsLung181329334CrossRefPubMed Sumi, M, Kagohashi, K, Satoh, H, Ishikawa, H, Funayama, Y, Sekizawa, K 2003Endostatin levels in exudative pleural effurfsionsLung181329334CrossRefPubMed
20.
Zurück zum Zitat Light, RW, Girard, WM, Jenkinson, SG, George, RB 1980Parapneumonic effusionsAm J Med69507511CrossRefPubMed Light, RW, Girard, WM, Jenkinson, SG, George, RB 1980Parapneumonic effusionsAm J Med69507511CrossRefPubMed
21.
Zurück zum Zitat Ocaña, I, Martínez-Vázquez, JM, Segura, RM, Fernández Sevilla, T, Capdevila, JA 1983Adenosine deaminase in pleural fluids: test for diagnosis of tuberculous pleural effusionChest845153PubMed Ocaña, I, Martínez-Vázquez, JM, Segura, RM, Fernández Sevilla, T, Capdevila, JA 1983Adenosine deaminase in pleural fluids: test for diagnosis of tuberculous pleural effusionChest845153PubMed
22.
Zurück zum Zitat Sahn, SA 1987Malignant pleural effusionSemin Respir Med94353 Sahn, SA 1987Malignant pleural effusionSemin Respir Med94353
23.
Zurück zum Zitat Light, RW, MacGregor, MI, Luchsinger, PC, Ball, WC 1972Pleural effusions: diagnostic separation of transudates and exudatesAn Intern Med77507513 Light, RW, MacGregor, MI, Luchsinger, PC, Ball, WC 1972Pleural effusions: diagnostic separation of transudates and exudatesAn Intern Med77507513
24.
Zurück zum Zitat Wang, B, Wiong, Q, Shi, Q, Tan, D, Le, X, Xie, K 2001Genetic disruption of host nitric oxide synthase II gene impairs melanoma-induced angiogenesis and suppresses pleural effusionInt J Cancer916076011CrossRefPubMed Wang, B, Wiong, Q, Shi, Q, Tan, D, Le, X, Xie, K 2001Genetic disruption of host nitric oxide synthase II gene impairs melanoma-induced angiogenesis and suppresses pleural effusionInt J Cancer916076011CrossRefPubMed
25.
Zurück zum Zitat Milligan, SA, Owens, MW, Grisham, MB 1996Augmentation of cytokine-induced nitric-oxide synthesis by hydrogen peroxideAm J Physiol271114120 Milligan, SA, Owens, MW, Grisham, MB 1996Augmentation of cytokine-induced nitric-oxide synthesis by hydrogen peroxideAm J Physiol271114120
26.
Zurück zum Zitat D’Arcangelo, D, Facchiano, F, Barlucchi, LM, et al. 2000Acidosis inhibits endothelial cell apoptosis and function and induces basic fibroblastic growth factor and vascular endothelial growth factor expressionCirc Res86312318PubMed D’Arcangelo, D, Facchiano, F, Barlucchi, LM,  et al. 2000Acidosis inhibits endothelial cell apoptosis and function and induces basic fibroblastic growth factor and vascular endothelial growth factor expressionCirc Res86312318PubMed
27.
Zurück zum Zitat Yanagawa, H, Takeuchi, E, Suzuki, Y, Ohmoto, Y, Bando, H, Sone, S 1999Vascular endothelial growth factor in malignant pleural effusion associated with lung cancerCancer Immunol Immunother48396400CrossRefPubMed Yanagawa, H, Takeuchi, E, Suzuki, Y, Ohmoto, Y, Bando, H, Sone, S 1999Vascular endothelial growth factor in malignant pleural effusion associated with lung cancerCancer Immunol Immunother48396400CrossRefPubMed
28.
Zurück zum Zitat Cheng, D, Rodriguez, RM, Perkett, EA, et al. 1999Vascular endothelial growth factor in pleural fluidChest116760765CrossRefPubMed Cheng, D, Rodriguez, RM, Perkett, EA,  et al. 1999Vascular endothelial growth factor in pleural fluidChest116760765CrossRefPubMed
29.
Zurück zum Zitat König, JE, Tolnay, E, Wiethege, T, Müller, KM 2000Co-expression of vascular endothelial growth factor and its receptor flt-1 in malignant pleural mesotheliomaRespiration673640CrossRefPubMed König, JE, Tolnay, E, Wiethege, T, Müller, KM 2000Co-expression of vascular endothelial growth factor and its receptor flt-1 in malignant pleural mesotheliomaRespiration673640CrossRefPubMed
30.
Zurück zum Zitat Strizzi b, , Catalano, A, Vianale, G, et al. 2001Vascular endothelial growth factor is an autocrine growth factor in human malignant mesotheliomaJ Pathol193468475CrossRefPubMed Strizzi b, , Catalano, A, Vianale, G,  et al. 2001Vascular endothelial growth factor is an autocrine growth factor in human malignant mesotheliomaJ Pathol193468475CrossRefPubMed
31.
Zurück zum Zitat Yeo, KT, Wang, HH, Nagy, JA, et al. 1993Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusionsCancer Res5329122918PubMed Yeo, KT, Wang, HH, Nagy, JA,  et al. 1993Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusionsCancer Res5329122918PubMed
32.
Zurück zum Zitat Kraft, A, Weindel, K, Ochs, A, Marth, C, et al. 1999Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant diseaseCancer85178187CrossRefPubMed Kraft, A, Weindel, K, Ochs, A, Marth, C,  et al. 1999Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant diseaseCancer85178187CrossRefPubMed
33.
Zurück zum Zitat Zebrowski, BK, Yano, S, Liu, W 1999Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusionsClin Cancer Res533643368PubMed Zebrowski, BK, Yano, S, Liu, W 1999Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusionsClin Cancer Res533643368PubMed
34.
Zurück zum Zitat Aoki, Y, Tosato, G 2001Vascular endothelial growth factor/vascular permeability factor in the pathogenesis of primary effusion lymphomasLeuk Lymphoma41229237PubMed Aoki, Y, Tosato, G 2001Vascular endothelial growth factor/vascular permeability factor in the pathogenesis of primary effusion lymphomasLeuk Lymphoma41229237PubMed
35.
Zurück zum Zitat Strizzi, L, Vianale, G, Catalano, A, Muraro, R, Mutti, L, Procopio, A 2001Basic fibroblast growth factor in mesothelioma pleural effusions correlation with patient survival and angiogenesisInt J Oncol1810931098PubMed Strizzi, L, Vianale, G, Catalano, A, Muraro, R, Mutti, L, Procopio, A 2001Basic fibroblast growth factor in mesothelioma pleural effusions correlation with patient survival and angiogenesisInt J Oncol1810931098PubMed
36.
Zurück zum Zitat Momi, H, Matsuyama, W, Inoue, K, et al. 2002Vascular endothelial growth factor and proinflammatory cytokines in pleural effusionsRespir Med96817822CrossRefPubMed Momi, H, Matsuyama, W, Inoue, K,  et al. 2002Vascular endothelial growth factor and proinflammatory cytokines in pleural effusionsRespir Med96817822CrossRefPubMed
37.
Zurück zum Zitat Hamed, EA, EI-Noweihi, AM, Mohamed, AZ, Mahmoud, A 2004Vasoactive mediators (VEGF and TNF-alpha) in patients with malignant and tuberculous pleural effusionsRespirology98186CrossRefPubMed Hamed, EA, EI-Noweihi, AM, Mohamed, AZ, Mahmoud, A 2004Vasoactive mediators (VEGF and TNF-alpha) in patients with malignant and tuberculous pleural effusionsRespirology98186CrossRefPubMed
38.
Zurück zum Zitat Iruela-Arispe, ML, Porter, P, Bornstein, P, Sage, EH 1996Thrombospondin-1, an inhibitor of angiogenesis, is regulated by progesterone in the human endometriumJ Clin Invest97403412PubMed Iruela-Arispe, ML, Porter, P, Bornstein, P, Sage, EH 1996Thrombospondin-1, an inhibitor of angiogenesis, is regulated by progesterone in the human endometriumJ Clin Invest97403412PubMed
39.
Zurück zum Zitat DiPietro, LA, Nebgen, DR, Polverini, PJ 1994Downregulation of endothelial cell thrombospondin 1 enhances in vitro angiogenesisJ Vasc Res31178185PubMed DiPietro, LA, Nebgen, DR, Polverini, PJ 1994Downregulation of endothelial cell thrombospondin 1 enhances in vitro angiogenesisJ Vasc Res31178185PubMed
40.
Zurück zum Zitat Tolsma, SS, Volpert, OV, Good, DJ, Frazier, WA, Polverini, PJ, Bouck, N 1993Peptides derived from two separate domains of the matrix protein thrombospondin 1 have anti-angiogenic activityJ Cell Biol122497511CrossRefPubMed Tolsma, SS, Volpert, OV, Good, DJ, Frazier, WA, Polverini, PJ, Bouck, N 1993Peptides derived from two separate domains of the matrix protein thrombospondin 1 have anti-angiogenic activityJ Cell Biol122497511CrossRefPubMed
41.
42.
Zurück zum Zitat Albo, D, Berger, DH, Wang, TN, Hu, X, Rothman, V, Tuszynski, GP 1997Thrombospondin-1 and transforming growth factor-beta 1 promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin systemSurgery122493500CrossRefPubMed Albo, D, Berger, DH, Wang, TN, Hu, X, Rothman, V, Tuszynski, GP 1997Thrombospondin-1 and transforming growth factor-beta 1 promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin systemSurgery122493500CrossRefPubMed
Metadaten
Titel
Angiogenic Factors and Angiogenesis Inhibitors in Exudative Pleural Effusions
verfasst von
Eva Ruiz, MD
Carmen Alemán, MD
José Alegre, MD
Jasone Monasterio, MD
Rosa Ma Segura, PhD
Lluis Armadans, MD
Ana Vázquez, Ph
Teresa Soriano, Ph
Tomás Fernández de Sevilla, MD
Publikationsdatum
01.06.2005
Erschienen in
Lung / Ausgabe 3/2005
Print ISSN: 0341-2040
Elektronische ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-004-2533-0

Weitere Artikel der Ausgabe 3/2005

Lung 3/2005 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.